[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-intractable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-intractable":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,70,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100600249","sensory-spinal-cord-stimulation-100600249",false,"NCT07095036","Sensory Spinal Cord Stimulation","Generating Artificial Sensory Perceptions Using Spinal Cord Stimulation","Inclusion Criteria:\n\n* Male and female patients 18-85 years old\n* Undergoing SCS implantation for treatment of chronic pain\n* Subjects with ability to walk 10m without assistance\n* Provides written consent for the study\n\nExclusion Criteria:\n\n* Subjects with high risk of falling\n* Refusal to participate in study\n* Subjects lacking consent capacity","ALL","18 Years","85 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this research study is to identify sensations that can be evoked with spinal cord stimulation (SCS) and to understand how these sensations change when stimulation parameters are modified.",[27,28,29],"Pain Management","Pain, Intractable","Pain, Chronic Disease","RECRUITING","2026-02-02",{"date":33,"type":34},"2026-02-04","ACTUAL",{"date":36,"type":34},"2026-01-06",{"date":38,"type":21},"2028-09-01",{"name":40,"class":41},"University of North Carolina, Chapel Hill","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100561939","early-phase-1-a-study-of-the-safety-and-tolerability-of-ga-in-the-treatment-of-patients-with-refractory-neuropathic-pain-100561939","NCT06596681","A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain","Inclusion Criteria:\n\n1. Patients with a definitive diagnosis of neuropathic pain, including but not limited to painful diabetic peripheral neuropathy, trigeminal neuralgia, and post-stroke pain, aged 18-65 years old (regardless of gender), with:\n\n   1. Regularised treatment with conventional medical therapy (including, but not limited to, medication, physiotherapy, cognitive therapy, nerve blocks and other non-invasive or minimally invasive treatments) for at least 3 months with no symptomatic relief or emergence of tolerance, as assessed by the investigator\n   2. Pharmacological treatment means a full course of treatment with at least two first-line medications, as assessed by the investigator\n2. Mean visual analogue scale (VAS) value ≥4 cm and\u002For mean numerical rating scale (NRS) value ≥4 points within one week of baseline at enrolment\n3. Subjects who have had a stable analgesic regimen for at least 30 days prior to the intensity of pain described in Inclusion Criterion 2 and agree not to arbitrarily change the type and dose of medication that they are currently taking until the end of the period of assessment of the effectiveness of this trial, as assessed by the investigator\n4. Subjects volunteered to participate in the trial and gave fully informed consent to sign an informed consent form\n5. Have stable neurological status as assessed by the researcher through motor, sensory and reflex functions\n6. Subjects are considered reliable and able to comply with the trial protocol (e.g., able to understand and complete relevant scales), visit protocols, and medication administration, according to the investigator's judgement\n7. Subjects of childbearing potential agree to sign an informed consent form and have no plans to have children during the study period and voluntarily use effective contraception (oral contraceptives are prohibited) and do not plan to donate sperm or eggs\n\nExclusion Criteria:\n\n* 1.In patients with painful diabetic peripheral neuropathy, amputation due to diabetes mellitus or large (≥3cm) and\u002For gangrenous ulcers on the lower limbs 2.Currently diagnosed with progressive neurological disorders such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, tumours of the brain or spinal cord, and neurodegenerative disorders, as determined by the investigators 3.Have a chronic systemic disease that, as assessed by the investigator, may affect the subject's participation in the study, including but not limited to:\n\n  1. suffering from severe cardiopulmonary disease such as unstable angina, myocardial infarction, severe arrhythmia, recurrent asthma attacks, etc;\n  2. Malignant tumours of the central nervous system or other systems. 4.Current status such as coagulation disorders, bleeding tendencies, platelet dysfunction, severely reduced function due to underlying cardiac\u002Fpulmonary disease, progressive peripheral vascular disease, or poorly controlled diabetes mellitus, and subjects who may be suffering from a relevant disease state that affects surgery as assessed by the investigator 5.Currently on anticoagulants and unable to stop them 6.Localised infection or active systemic infection at the anticipated surgical access site 7.History of previous intracranial surgical treatment (except for minimally invasive paracentesis for diagnostic tests, etc.) 8.Patients with severe psychiatric symptoms (e.g., major depression, schizophrenia, etc.) or significant suicidal tendencies or assessed by the investigator to be unable to complete the clinical trial 9. Pre-existing or concomitant severe hepatic dysfunction, renal dysfunction, cardiac dysfunction (in which severe hepatic dysfunction is defined as ALT ≥ 2.0 times the upper limit of normal or AST ≥ 2.0 times the upper limit of normal; severe renal dysfunction refers to a CRE ≥ 1.5 times the upper limit of normal or an eGFR \\\u003C 40mL\u002Fmin\u002F1.73m2; and severe cardiac dysfunction refers to an NYHA score of grade 3-4) ，delirium, hypotension, epilepsy, glaucoma, myelosuppression or leukopenia, severe central nervous system depression, or coma from any cause 10. Subjects with abnormal laboratory test values:\n\n  \u003C!-- -->\n\n  1. white blood cell count \\\u003C3.5 x 109\u002FL and neutrophil count \\\u003C1.0 x 109\u002FL\n  2. Platelet (PLT) \\\u003C75 x 109\u002FL\n  3. Coagulation: prothrombin time and activated partial thromboplastin time \\>1.5 x ULN\n  4. Blood adeno-associated virus (AAV) antibody titre \\>1:1000 11.Patients taking drugs that cause granulocyte deficiency or have myelosuppressive effects 12.Patients with granulocyte deficiency or severe granulocytopenia due to prior clozapine use 13.Patients with contraindications and\u002For allergies to medications during the trial (e.g. clozapine or other components of clozapine, contrast agents, etc.) 14.Have gastrointestinal diseases (Crohn's disease, acute or chronic pancreatitis, paralytic intestinal obstruction, etc.) or major gastrointestinal surgeries that affect the absorption, metabolism and excretion of drugs, etc.\n\n     15.Subjects had received any gene or cellular therapy 16. Known history of alcohol, drug abuse 17.Patients participating in other clinical trials or applying other investigational biologics, drugs or devices within six months prior to screening 18.Contraindications to MRI and functional MRI (e.g. claustrophobia, metallic foreign bodies in the body) 19.Clozapine-related serious adverse reactions are considered a screening failure if they occur during the screening period, at the judgement of the investigator","65 Years",{"count":51,"type":21},6,[53],"EARLY_PHASE1","Previous studies have shown that the anterior cingulate cortex is involved in the regulation of pain and its associated negative emotions, that pyramidal neurons are highly excitable in chronic neuropathic pain conditions, and that silencing of pyramidal neurons can eliminate pain. The aim of this study was to evaluate the safety, tolerability, and efficacy of intracranial injection of GA (containing the hM4Di gene) in the anterior cingulate cortex in combination with oral clozapine for the treatment of refractory neuropathic pain.",[28],[57,58,59,60],"Refractory neuropathic pain","GA","clozapine","safety","2026-01-20",{"date":63,"type":34},"2026-01-22",{"date":65,"type":34},"2024-09-11",{"date":67,"type":21},"2026-06-30",{"name":69,"class":41},"Beijing Tiantan Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":42},"100469837","medullary-stimulation-for-the-treatment-of-refractory-neck-pain-s2m-100469837","NCT05398003","Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)","Evaluation of Multimodal Medullary Stimulation in Refractory Neck and Upper Limb Pain","S2M","Inclusion criteria:\n\n* Patients aged 18 to 85 years\n* Patients with chronic neck and upper limb pain (according to HAS criteria for spinal cord stimulation)\n* Patients must be able to give informed consent and must have signed an informed consent\n* Affiliation to the health insurance\n* A negative pregnancy test for women of childbearing potential\n* Women of childbearing potential must use an appropriate contraceptive method(s) during the clinical trial\n\nNon-inclusion criteria:\n\n* Drug or alcohol abuse\n* Any medical or psychological problem that may interfere with the proper conduct of the study protocol (e.g., cancer with limited life expectancy)\n* Difficulty with follow-up\n* Pregnant or breastfeeding women\n* Women of childbearing potential who are not using contraception\n* Adults under legal protection (guardianship, curatorship, \"sauvegarde de justice\") or deprived of liberty\n* Exclusion period for another study\n* Participation in another interventional study whose primary objective is based on pain.\n\nExclusion criteria:\n\n\\- 7-day post-implantation test phase negative",{"count":79,"type":21},12,[24],"Number of centres planned : 1 (CHU Nantes)\n\nDesign : Randomized, Prospective\n\nPlanning of the study :\n\n* Total duration: 34 months\n* Recruitment period: 24 months.\n* Follow-up time per patients : 7-10 months\n\nExpected number of cases : 12\n\nTreatment, procedure, combination of procedures under consideration :\n\nDuring the study, patients will be implanted with the WAVEWRITER ALPHA™ system with the objective of decreasing patient pain with a spinal cord stimulation mode.\n\nThere will be a random draw on the order of the stimulation program:\n\n* the tonic stimulation \"LF\": In tonic mode, the electrical stimulation of the sensory fibers of the posterior cords of the spinal cord induces local paresthesias\n* burst stimulation (or \"burst\")\n* high frequency\" stimulation (1000 Hz) \"High frequency: HF\".\n* combined tonic + burst stimulation\n* combined tonic + high frequency stimulation",[28],[84,85],"Medullary stimulation","refractory neck pain","2024-11-14",{"date":88,"type":34},"2024-11-18",{"date":90,"type":34},"2022-11-23",{"date":92,"type":21},"2026-09-23",{"name":94,"class":41},"Nantes University Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":42},"100497757","app-based-precise-management-system-of-chronic-intractable-pain-100497757","NCT05761392","APP-based Precise Management System of Chronic Intractable Pain","Precise Management System (PreMaSy) of Chronic Intractable Pain Based on a Remote and Wireless Spinal Cord Stimulation System","PreMaSy","Inclusion Criteria:\n\n* Have been clinically diagnosed with chronic, intractable pain for more than three months.\n* At enrollment, the average pain intensity is no least than 5 out of 10 cm on visual analogue scale.\n* At enrollment, the age is no younger than 18-year-old.\n* Ineffective or unsatisfactory conservative treatments, including but limited to: oral medication, nerve block, epidural corticosteroids, physical and psychological rehabilitation therapy, and chiropractic care.\n* Voluntary to take the trial and sign the informed consent.\n* Good compliance and ability to complete post-operative follow-ups.\n* Basic ability to read and use a mobile phone or having a caregiver who can.\n\nExclusion Criteria:\n\n* Bleeding complications or coagulation disorders.\n* Mental or cognitive disorders leading to inability to complete implantation surgery or post-operative follow-up.\n* Issues with spinal cord or vertebrates that are not suitable for implantation surgery.\n* Systemic active infections or local infections around the surgery area.\n* Pregnancy, breast-feeding, plan to be pregnant or unwilling to use contraceptive methods.\n* Metastatic malignant tumors or untreated malignant tumors.\n* Life expectancy of less than one year.\n* Already provided with a medication pump and\u002For other implanted devices.\n* Need for therapy or examination that must not have an implanted pulse generator (IPG), such as magnetic resonance imaging (MRI) and thermo-therapy.\n* Heavily addicted to alcohol or drugs.\n* VAS improvement less than 50% or stimulation intolerance during the test period.\n* Unable to complete long-term online follow-ups because of hardware issues such as internet, mobile phones, and so on.\n* Unwilling to participate.\n* Other inappropriate situations determined by the investigators.",{"count":104,"type":21},120,[24],"The goal of this clinical trial is to learn about a new management system in chronic and stubborn pain patients who accept therapy of spinal cord stimulation (SCS). Usually, these patients are required to take long-term follow-ups to ensure that the stimulator works well. The main questions it aims to answer are:\n\n* Is it better to improve the patient's quality of life than the current conventional follow-up?\n* Is it better to relieve pain in the long term than the current conventional follow-up?\n* Is it possible to be applied to a large population of chronic pain patients? Participants will be randomly assigned to either a control group or an interventional group.\n\nParticipants in the control group will be given the standard SCS implantation surgery and asked to complete the conventional follow-up (at least 1-, 3-, and 6-month post-operative).\n\nParticipants in the interventional group will be given the standard SCS implantation surgery and asked to do the following things:\n\n* Take the daily pain self-assessment questions on a mobile phone APP.\n* Take the monthly healthy status self-assessment questionnaires on a mobile phone APP.\n* Take the conventional follow-up (at least 1-, 3-, and 6-month post-operative). Researchers will compare the two groups to see if the life quality of the interventional group is improved.",[108,28],"Pain, Chronic",[110,111,112,113],"Pain management","Spinal cord stimulation","Remote programming","Mobile health","2023-03-07",{"date":116,"type":34},"2023-03-09",{"date":118,"type":34},"2022-09-26",{"date":120,"type":21},"2026-09-25",{"name":122,"class":41},"Beijing Tsinghua Chang Gung Hospital"]